16th January 2011 - New research


BasedPLoS One [2010] 5 (12) : e15298 (Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T) Complete abstract

The purpose of the present study was to investigate the efficacy of Amantadine in people with Parkinson's Disease suffering from dyskinesias. Dyskinesias, which are involuntary movements, are some of the major complications that impair quality of life for some people with Parkinson's disease. They are normally caused by an excess of dopaminergic drugs, such as L-dopa in its various forms, and dopamine agonists. For more information go to Dyskinesia in Parkinson's Disease. A controlled clinical trial was carried out using
300mg per day of Amantadine, which is also marketed as Symmetrel. For more information go to Symmetrel. Using the Rush Dyskinesia Rating Scale (RDRS), 64% of those people taking Amantadine improved, whereas only 16% of those people taking the placebo improved. Some Parkinson's Disease symptoms improved, but others did not. Results from the present study demonstrated that Amantadine exhibited beneficial effects against dyskinesias in 60% to 70% of people with Parkinson's Disease. However, the study did not indicate the side effects caused as a result of taking Amantadine. For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports





2006-2010  Viartis
2015-06-29 00:11:27
[email protected]